Literature DB >> 17442986

Methylguanine methyltransferase testing in glioblastoma: when and how?

Roger Stupp, Monika E Hegi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17442986     DOI： 10.1200/JCO.2006.09.7139

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

Review 1.  O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

Authors:  John R Silber; Michael S Bobola; A Blank; Marc C Chamberlain
Journal:  Biochim Biophys Acta       Date:  2012-01-08

2.  Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.

Authors:  Carmen Balańa; Cristina Carrato; José Luis Ramírez; Andrés Felipe Cardona; Mireia Berdiel; José Javier Sánchez; Miquel Tarón; Cristina Hostalot; Eva Musulen; Aurelio Ariza; Rafael Rosell
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

3.  MGMT gene promoter methylation in pediatric glioblastomas.

Authors:  Arti Srivastava; Ayushi Jain; Prerana Jha; Vaishali Suri; Mehar Chand Sharma; Supriya Mallick; Tarun Puri; Deepak Kumar Gupta; Aditya Gupta; Chitra Sarkar
Journal:  Childs Nerv Syst       Date:  2010-06-29       Impact factor: 1.475

4.  O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.

Authors:  Sabine Spiegl-Kreinecker; Christine Pirker; Martin Filipits; Daniela Lötsch; Johanna Buchroithner; Josef Pichler; Rene Silye; Serge Weis; Michael Micksche; Johannes Fischer; Walter Berger
Journal:  Neuro Oncol       Date:  2009-10-15       Impact factor: 12.300

5.  Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.

Authors:  Lucie Karayan-Tapon; Véronique Quillien; Joëlle Guilhot; Michel Wager; Gaëlle Fromont; Stephan Saikali; Amandine Etcheverry; Abderrahmane Hamlat; Delphine Loussouarn; Loïc Campion; Mario Campone; François-Marie Vallette; Catherine Gratas-Rabbia-Ré
Journal:  J Neurooncol       Date:  2009-10-20       Impact factor: 4.130

Review 6.  O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction.

Authors:  Marta Brell; Javier Ibáñez; Avelina Tortosa
Journal:  BMC Cancer       Date:  2011-01-26       Impact factor: 4.430

7.  Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations.

Authors:  Margarita García; Ana Clopés; Jordi Bruna; María Martínez; Eduard Fort; Miguel Gil
Journal:  Cancer Manag Res       Date:  2009-10-30       Impact factor: 3.989

8.  Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.

Authors:  Barbara Ingold; Peter Schraml; Frank L Heppner; Holger Moch
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

9.  BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1α stability and MGMT expression.

Authors:  L Persano; F Pistollato; E Rampazzo; A Della Puppa; S Abbadi; C Frasson; F Volpin; S Indraccolo; R Scienza; G Basso
Journal:  Cell Death Dis       Date:  2012-10-18       Impact factor: 8.469

10.  DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients.

Authors:  Torbjörn K Nilsson; Zarah M Löf-Öhlin; Xiao-Feng Sun
Journal:  Int J Oncol       Date:  2012-10-30       Impact factor: 5.650
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.